Drug-Eluting Stent
At Issue: Debate over DAPT duration endures
Since the advent of drug-eluting stents, there has been a debate in the intervention community over how long dual antiplatelet therapy should last after PCI.
Bioadaptor may flatten event curve after PCI, including in complex lesions
WASHINGTON — A bioadaptor implant adaptable to vessel physiology was linked to fewer target lesion failure events after 6 months compared with a drug-eluting stent, including in high-risk lesions, researchers reported.
Top in cardiology: Implant for coronary artery disease; Fasting vs. no fasting
Results from the INFINITY-SWEDEHEART trial showed that Elixir Medical’s drug-eluting coronary implant was noninferior to a drug-eluting stent for target lesion failure at 1 year.
Coronary implant noninferior to DES at 1 year, tied to event reduction after 6 months
The bioadaptor implant adaptable to vessel physiology was noninferior to a drug-eluting stent for target lesion failure at 1 year, and reduced event rates vs. the DES after 6 months, researchers reported.
Adaptable implant improves outcomes vs. drug-eluting stent at 2 years in patients with CAD
A drug-eluting coronary implant adaptable to vessel physiology with uncaging elements was linked to less target lesion failure and target vessel failure at 2 years compared with a drug-eluting stent, researchers reported.
FDA grants breakthrough device designation for resorbable magnesium scaffold for CLTI
Biotronik announced it was granted breakthrough device designation from the FDA its below-the-knee resorbable magnesium scaffold for the treatment of chronic limb-threatening ischemia.
Triple drug-coated stent may reduce risk for stent thrombosis, target lesion failure
SAN FRANCISCO — The first-time application of a triple-drug, site-specific antithrombotic therapy on a stent platform was safe and effective for managing thrombotic and bleeding risk after PCI, data presented at TCT 2023 show.
Novel bioabsorbable scaffold for tibial vessels safe in first-in-human study
A novel bioabsorbable scaffold for tibial vessels was safe and associated with a low rate of restenosis in patients with Rutherford class 3, 4 or 5 peripheral artery disease, according to the results of a first-in-human study.
LIFE-BTK trial: Bioresorbable scaffold did not disrupt wound healing in patients with CLTI
An everolimus-eluting bioresorbable scaffold did not affect wound healing compared with angioplasty in patients with chronic limb-threatening ischemia, according to new data from the LIFE-BTK trial.
Stopping aspirin 1 month after drug-eluting stent implantation feasible for patients with ACS
SAN FRANCISCO — In patients with ACS, stopping aspirin for ticagrelor monotherapy within 1 month of receiving a drug-eluting stent did not increase adverse CV and bleeding events compared with 12 months of dual antiplatelet therapy.